Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-C motif chemokine receptor-like 2 (CCRL2) is an atypical, non-signaling seven-transmembrane G protein-coupled receptor that belongs to the chemokine receptor family. Unlike classical chemokine receptors, CCRL2 lacks the conserved DRYLAIV motif required for G-protein coupling and intracellular signaling. Instead, it functions primarily as a scavenger or presenting molecule, binding ligands such as CCL19 and chemerin to modulate local chemokine gradients and regulate leukocyte trafficking and immune responses. CCRL2 is highly expressed on activated myeloid cells, including neutrophils, monocytes, and dendritic cells, as well as endothelial cells.
In pathological contexts, CCRL2 is upregulated in various inflammatory conditions, such as rheumatoid arthritis, and plays complex roles in oncology. It is significantly overexpressed in high-risk myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML), particularly in subtypes harboring TP53 mutations and erythroid features. Consequently, CCRL2 has emerged as a promising therapeutic target. Experimental therapies, such as anti-CCRL2 antibody-drug conjugates (ADCs) armed with cytotoxic payloads like pyrrolobenzodiazepine (PBD), have demonstrated selective cytotoxicity against TP53-mutated leukemia cells while sparing healthy hematopoietic stem cells. Additionally, blocking CCRL2-chemerin interactions is being explored to enhance anti-tumor immunity and manage inflammatory diseases.
Targeted cytotoxicity via antibody-drug conjugate internalization and receptor blockade of chemokine binding
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-C motif chemokine receptor-like 2 (CCRL2).